ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/ATR
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/ATR
6
trial(s) found.
NCT06433219
Advanced
Phase 2
Recruiting
An Open-label, Multicenter, Randomized Phase 2 Study of the ATR Inhibitor Tuvusertib in Combination With the PARP Inhibitor Niraparib or the ATM Inhibitor Lartesertib in Participants With BRCA Mutant and/or Homologous Recombination deficiency (HRD)-Positive Epithelial Ovarian Cancer That Progressed on Prior PARP Inhibitor Therapy (DDRiver EOC 302) (
MS201924-0002
)
ATM inhibitor
ATR inhibitor
PARP inhibitor
Ovarian cancer
NSW
2170 - Liverpool - Liverpool Hospital
NCT05269316
Advanced
Phase 1 / Phase 2
Recruiting
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors (
IMP9064-101
)
ATR inhibitor
PARP inhibitor
NOT Central nervous system cancer
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (COMPLETED)
WA
6009 - Nedlands - Linear Clinical Research (COMPLETED)
ACTRN12619001185156
Advanced
Phase 2
Recruiting
A Phase II signal-seeking trial targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification to determine the clinical benefit rate. (
IGNITE
)
ATR inhibitor
Adavosertib
Ceralasertib
WEE1 inhibitor
cancer therapy
cancer therapy,ATR-targeting
cancer therapy,WEE1-targeting
+ ATR inhibitor
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Ovarian cancer
Primary fallopian tube serous carcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT05450692
Advanced
Phase 3
Active not recruiting
A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy:
LATIFY
ATR inhibitor
anti-PD-L1 monoclonal antibody
taxane
Non-small cell lung cancer
NSW
2480 - Lismore - Lismore Base Hospital
2500 - Wollongong - Wollongong Hospital
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05338346
Advanced
Phase 1
Not recruiting
A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (
ATRIUM
)
ATR inhibitor
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
ACTRN12621000991819
Advanced
Not Applicable
Status unknown
A Feasibility Trial of Patient Derived Cell Culture (PDCC) Chemosensitivity in Head and Neck Carcinoma (HNC) (
PDCCiHNC
)
ALK inhibitor
ALK inhibitor,first generation
ATR inhibitor
BCR-ABL1 inhibitor
BCR-ABL1 inhibitor,second generation
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CRAF/FLT3/KIT/PDGFR/VEGFR inhibitor
CRAF inhibitor
Carboplatin
Ceralasertib
Cisplatin
Crizotinib
Dactolisib
Dasatinib
Docetaxel
Doxorubicin
EGFR inhibitor
EGFR inhibitor,first generation
Erlotinib
Etoposide
FLT3 inhibitor
Fluorouracil
Gemcitabine
Itraconazole
JAK1/JAK2 inhibitor
JAK1 inhibitor
JAK2 inhibitor
KIT inhibitor
MET inhibitor
MET inhibitor,type 1
Methotrexate
PDGFRA inhibitor
PDGFR inhibitor
PI3K/mTOR inhibitor
PI3K inhibitor
Paclitaxel
Palbociclib
Pemetrexed
RAF inhibitor
ROS1 inhibitor
Ruxolitinib
SMO inhibitor
SRC inhibitor
Sorafenib
VEGFR inhibitor
Vinorelbine
Vistusertib
YES1 inhibitor
anthracycline
antifolate
antimetabolite
cancer therapy
cancer therapy,ALK-targeting
cancer therapy,ATR-targeting
cancer therapy,BCR-ABL1-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CRAF-targeting
cancer therapy,EGFR-targeting
cancer therapy,FLT3-targeting
cancer therapy,JAK1-targeting
cancer therapy,JAK2-targeting
cancer therapy,KIT-targeting
cancer therapy,MET-targeting
cancer therapy,PDGFR-targeting
cancer therapy,PDGFRA-targeting
cancer therapy,PI3K-targeting
cancer therapy,RAF-targeting
cancer therapy,ROS1-targeting
cancer therapy,SMO-targeting
cancer therapy,SRC-targeting
cancer therapy,VEGFR-targeting
cancer therapy,YES1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
cytotoxic chemotherapy
fluoropyrimidine
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
platinum-based antineoplastic agent
taxane
topoisomerase inhibitor
vinca alkaloid
+ ATR inhibitor
Head and neck cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Active not recruiting (1)
Not recruiting (1)
Status unknown (1)
Recruitment Country and State
NSW (6)
WA (3)
QLD (3)
SA (2)
VIC (2)
TAS (1)
Phase
Phase 1 (1)
Phase 1 / Phase 2 (1)
Phase 2 (2)
Phase 3 (1)
Trial Type
Advanced (6)
Cancer Therapy Class
ATR
100%
PARP
33%
ATM
17%
WEE1
17%
PD-1/PD-L1
17%
PD-L1
17%
ALK
17%
BCR-ABL1
17%
CDK4
17%
CDK6
17%
CRAF
17%
EGFR
17%
FLT3
17%
JAK1
17%
JAK2
17%
KIT
17%
MET
17%
PDGFR
17%
PDGFRA
17%
PI3K
17%
RAF
17%
ROS1
17%
SMO
17%
SRC
17%
VEGFR
17%
YES1
17%
mTOR
17%
mTORC1
17%
mTORC2
17%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (3)
2170 - Liverpool - Liverpool Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
2031 - Randwick - Prince of Wales Hospital (1)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
7000 - Hobart - Royal Hobart Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
3004 - Melbourne, Southbank - Alfred Health (1)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (1)
Cancer Type
Cancer
Solid tumour
Gynaecological cancer
Ovarian cancer
Epithelial Ovarian Cancer
Fallopian tube cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Primary fallopian tube serous carcinoma
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Haematological malignancy
Head and neck cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy